KHARTCHENKO v. THE AMERICAN ONCOLOGIC HOSPITAL, INC.

CourtDistrict Court, D. New Jersey
DecidedSeptember 30, 2024
Docket1:23-cv-23043
StatusUnknown

This text of KHARTCHENKO v. THE AMERICAN ONCOLOGIC HOSPITAL, INC. (KHARTCHENKO v. THE AMERICAN ONCOLOGIC HOSPITAL, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
KHARTCHENKO v. THE AMERICAN ONCOLOGIC HOSPITAL, INC., (D.N.J. 2024).

Opinion

[ECF No. 17]

THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY CAMDEN VICINAGE

INNA KHARTCHENKO,

Plaintiff, Civil No. 23-23043 (ESK/EAP) v.

THE AMERICAN ONCOLOGIC HOSPITAL, INC. et al.,

Defendants.

OPINION

This matter comes before the Court on the motion of Defendants, the American Oncologic Hospital, Inc. (“AOH”), the Institute for Cancer Research (named as Fox Chase Cancer Center) (“FCCC”), and Temple University Health System, Inc. (“TUHS”) (collectively, the “Corporate Defendants”) to Strike and Seal Attorney-Client Privileged Communications, ECF No. 17. Plaintiff Inna Khartchenko opposed the motion, ECF No. 23, and the Corporate Defendants filed a reply, ECF No. 24. The Court has reviewed the parties’ submissions and decides this matter without oral argument pursuant to Federal Rule of Civil Procedure 78(b) and Local Civil Rule 78.1. For the following reasons, the motion will be GRANTED IN PART and DENIED IN PART. FACTUAL BACKGROUND1 A. The Parties Defendant AOH was one of the nation’s first cancer hospitals established in 1904, and in union with the Institute for Cancer Research, formed FCCC in 1974. See ECF No. 1-3, First

1 The facts are taken directly from the First Amended Complaint. Amended Complaint (“FAC”) ¶¶ 14-15. In 2012, FCCC became part of TUHS, and since then, the Corporate Defendants have operated as joint entities to service patients from across the world in the Greater Philadelphia region and South Jersey. Id. ¶¶ 16–18. Plaintiff Inna Khartchenko is an immigrant of Russian and Ukrainian origin with a Master of Science in Biochemistry and Molecular Biology and a Master of Business Administration. Id. ¶ 22. In approximately 2007, the Corporate Defendants hired Plaintiff as the Associate Director of

Business Development and in 2015, they promoted her to the Director of Technology Transfer. Id. ¶¶ 19-20. In 2018, her responsibilities were expanded to include New Ventures programs. Id. ¶ 21. According to the FAC, her employment was “without issue” until she (1) complained that Defendant Sangeeta Bardhan Cook, the Chief Innovation Officer for FCCC and Senior Vice President of Commercialization Strategy and Business Development for TUHS, made discriminatory comments to Plaintiff; (2) reported Cook for retaliating against her by attempting to deny her a necessary medical accommodation for her disability; and (3) objected to Defendants’ business dealings with a Russian company. Id. ¶¶ 7, 30. B. Defendant Cook’s Alleged Pattern of Discriminatory Conduct and Retaliation

Cook began her employment with the Corporate Defendants in August 2022. Id. ¶ 36. On October 27, 2022, Cook sent a Microsoft Teams message to Plaintiff about Corporate Defendants’ President and Chief Executive Officer, Robert Uzzo, and Corporate Defendants’ Cancer Center Director Jonathan Chernoff, remarking that Uzzo and Chernoff were “two white guys” who only cared about samples from underrepresented patient populations because the National Cancer Instituted “forced them” to care. Id. ¶¶ 39-40. Over the next several months, Cook made additional comments that Plaintiff found offensive, many of which were of an allegedly antisemitic nature. Id. ¶¶ 44-47. Plaintiff objected to Cook’s comments by explaining that many of her friends are Jewish and that she grew up with Jewish students and teachers. Id. ¶¶ 48-50. Beyond the antisemitic comments, Cook regularly made harassing comments about many of Plaintiff’s colleagues, some of which Plaintiff believed showed that Cook had a pattern of discrimination against persons with disabilities. Id. ¶¶ 51-56. In November 2022, Plaintiff went to the emergency room with extreme abdominal pain and was diagnosed with a serious ovarian condition. Id. ¶ 58. She reported to Cook that she was scheduled for surgery on January 9, 2023. Id. ¶ 59. Although Cook suggested that Plaintiff could

take Family and Medical Leave Act (“FMLA”) leave, Plaintiff opted to continue her previous remote work arrangement and continue working throughout her recovery, with sick time taken only as needed. Id. ¶¶ 60-70. Between January 12, 2023, and January 27, 2023, Plaintiff worked remotely while using approximately two sick days per week. Id. ¶ 71. During this time, Plaintiff recognized a change in Cook’s behavior toward her, as she began “to heavily scrutinize” her work. Id. ¶¶ 73-74. On January 23, 2023, Plaintiff decided to report Cook’s alleged pattern of discriminatory behavior—focusing on her antisemitic comments and increased scrutiny of Plaintiff’s work after her surgery—to Corporate Defendants’ Cancer Center Director, Jonathan Chernoff. Id. ¶¶ 75-77. Just days later, on

January 28, 2023, Cook informed Plaintiff that she had to retroactively use FMLA leave for her sick days after her surgery and that she could not work until she presented a physician’s clearance note. Id. ¶ 78. On January 30, 2023, Cook began to target Plaintiff’s work-from-home arrangement and presented Plaintiff with an accommodation form to be signed by her physician for her to remain working from home. Id. ¶ 81. Although Plaintiff’s accommodation request was approved through May 13, 2023, it was “imminently clear to Plaintiff” that Cook was beginning the process to revoke her remote work arrangement. Id. ¶ 87. On February 2, 2023, Plaintiff reported this increasing retaliation to Corporate Defendants’ Human Resources department, specifically Defendant Amber Medlin. Id. ¶¶ 84-85. Corporate Defendants purported to investigate Plaintiff’s complaints and interviewed Plaintiff on February 15, 2023, via Zoom from her home office in New Jersey. Id. ¶ 86. During the investigation period, Plaintiff alleges that she suffered stress that contributed to complications from her surgery. Id. ¶¶ 88-89. In the wake of the investigation, Cook publicly criticized Plaintiff, micromanaged her, made her look incompetent, and excluded her from important meetings. Id. ¶ 90. On April 14, 2023, Cook informed Plaintiff that she had to be on site three days per week

beginning May 1, 2023, because of her “director-level” position. Id. ¶ 92. Cook also instructed Plaintiff to write a return-to-office (“RTO”) plan for her team, even though she had not thought about office space. Id. ¶ 93. Cook rejected Plaintiff’s plan and sent RTO instructions to Plaintiff and her team. Id. Plaintiff objected to Cook’s plans to revoke the work-from-home arrangement for multiple reasons, but Cook refused to consider Plaintiff’s objections. Id. ¶¶ 94-95. C. Plaintiff’s Whistleblower Complaints Regarding the Corporate Defendants’ Business Affiliations

On March 28, 2023, Plaintiff participated in a Zoom meeting with Cook and Corporate Defendants’ Licensing Associate, Tatiana Venkova. Id. ¶ 99. Cook informed Plaintiff that, because Plaintiff spoke Russian, she needed her help negotiating with a company based out of Moscow, Russia (hereinafter the “Russian Company”) that held the rights to a promising anti-cancer drug. Id. ¶¶ 100-01. Plaintiff was “immediately apprehensive” about working on this project due to her Ukrainian heritage and the ongoing conflict between Russia and the Ukraine. Id. ¶¶ 104-05. She also worried that the Corporate Defendants’ affiliations with a Russian company could pose serious problems for Corporate Defendants both legally and ethically. Id. ¶ 106. Given her concerns, Plaintiff conducted approximately thirty minutes of research of publicly-available information and discovered that the Russian Company was owned by the Russian Venture Company—part of the Russian Direct Investment Fund—which has direct ties to the Russian government and was sanctioned by the United States for violations of international law. Id. ¶¶ 107-09.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Upjohn Co. v. United States
449 U.S. 383 (Supreme Court, 1981)
Commodity Futures Trading Commission v. Weintraub
471 U.S. 343 (Supreme Court, 1985)
LEAP Systems, Inc. v. MoneyTrax, Inc.
638 F.3d 216 (Third Circuit, 2011)
Tonka Corp. v. Rose Art Industries, Inc.
836 F. Supp. 200 (D. New Jersey, 1993)
Garlanger v. Verbeke
223 F. Supp. 2d 596 (D. New Jersey, 2002)
United Jersey Bank v. Wolosoff
483 A.2d 821 (New Jersey Superior Court App Division, 1984)
United States Ex Rel. Hunt v. Merck-Medco Managed Care, LLC
340 F. Supp. 2d 554 (E.D. Pennsylvania, 2004)
Wachtel v. Health Net, Inc.
482 F.3d 225 (Third Circuit, 2007)
Leonen v. Johns-Manville
135 F.R.D. 94 (D. New Jersey, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
KHARTCHENKO v. THE AMERICAN ONCOLOGIC HOSPITAL, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/khartchenko-v-the-american-oncologic-hospital-inc-njd-2024.